Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This study is looking for men with prostate cancer that has spread and is no longer responding to hormone therapy. You would need to have had your prostate cancer diagnosed as adenocarcinoma (a common type of prostate cancer) and show that it has spread to other parts of your body. Your cancer should also have gotten worse while you were on hormone therapy within the last six months.

You would need to have already received one type of advanced hormone treatment and one or two chemotherapy treatments, and your cancer should have progressed after these. It's also important that your testosterone levels are low due to ongoing hormone therapy. You'll need to provide a recent tissue sample from your tumour, and generally be well enough to take part in a study, assessed by a common health check. You may have also had other specific treatments like PARP inhibitors or Lu-PSMA, or been advised not to have them, or decided not to have them.

If you decide to join this study, you will be randomly assigned to receive either the new medicine, Opevesostat, or one of the standard hormone treatments (abiraterone acetate or enzalutamide). You might also take other medicines like hydrocortisone, fludrocortisone, prednisone, or dexamethasone, depending on your treatment group. Since it's an 'open-label' study, both you and your doctor will know which treatment you are receiving. You'll have regular hospital visits for check-ups, assessments, and to receive your medication. These visits will involve blood tests, scans, and physical exams to monitor your health and how your cancer is responding to treatment. The total duration of your participation will depend on how you respond to the treatment, but you will be followed carefully throughout the study and afterwards.